Vesicare is the first overactive bladder treatment at an approved dose to show a statistically significant increase in warning time before urination Christchurch, New Zealand – December 1, 2006 – ...

WALTHAM, Mass., April 3, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on ...

Solifenacin succinate 1mg/mL; oral susp; orange-flavor. Take once daily, followed by liquid (eg, water or milk). Avoid taking at the same time with food or other drinks. Missed dose: take as soon as ...

The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.

Nov. 23, 2004 — The U.S. Food and Drug Administration (FDA) has approved solifenacin succinate for the treatment of overactive bladder, erlotinib as second-line therapy for locally advanced or ...

The Scottish Medicines Consortium, Scotland’s equivalent to the National Institute for Health and Clinical Excellence in England and Wales, has decided to back the use of Astellas Pharma’s Vesicare ...

The US Food and Drug Administration (FDA) has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate (Vesicare, Astellas Pharma) for the treatment of overactive ...

Hi Doc Thanks for the reply to my earlier question about taking Vesicare & Trepiline for my bladder problems. I would just like to please know could I not change the dosage of Trepiline to, say, 25mg ...

CHICAGO Patients with overactive bladder who received the drug Vesicare reported lower incidence of dry mouth than those who received an immediate-release formulation of the generic drug oxybutynin, ...

Astellas tapped independent agency Roska Healthcare as consumer agency-of-record for Astellas’ new overactive bladder pill, Myrbetriq (mirabegron). The agency announced the win in August, just over a ...

Strategic Challenge: How do you become the #1 brand in a category no one wants to talk about? Let's face it…people don't want to talk about their bladder, let alone their overactive bladder (OAB) and ...

WALTHAM, Mass., April 3, 2008 Decision Resources, one ofthe world's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that a drug's effect on the reduction of ...